Research findings advance the development of HIV vaccine that induces broadly Neutralizing Antibodies. A team of Doctors at the Duke University describes both the pathway of HIV protective antibody development and a synthetic HIV outer envelope mimic that induces the antibodies with a vaccine. The goal is to develop HIV vaccination at a large scale. Health professionals believe that an HIV-1 vaccine induces broadly neutralizing antibodies. According to Barton F. Haynes, director of the Duke Human Vaccine Institute (DHVI), scientists will develop HIV vaccine.

Immune system responses to the virus

Previously, a team of senior health professionals at the University of Cambridge published papers on HIV vaccine. Experts believe that the research project on HIV vaccine will lead to the development of broadly neutralizing antibodies. The immunity of the infected person responds to the virus with unusual effort between different B-cell lineages and induces broadly neutralizing antibodies. The development of antibodies is a complicated procedure, and it is important to develop drugs for HIV as early as possible.

The use of blueprint to build synthetic molecules

A team at Memorial Sloan Kettering Cancer Center, led by Samuel Danishefsky, will use blueprints to create synthetic molecules that mimic the HIV site targeted in infection.

Health experts at the Duke University claim that they will test if these synthetic molecules induce antibodies in the vaccine of a non-human primate. They aim to develop HIV vaccination by the end of this year. Researchers believe that the synthetic molecules have the ability to target the affected site more quickly than the non-synthetic molecules.

It means the synthetic molecules could help in the development of HIV vaccination. Paul Biegler at the Duke University believes that all studies support the concept of designing a vaccine, and he will combine multiple HIV components in his research. However, experts need more time and further research to accomplish this project.